Lupin informs about press release

03 Apr 2020 Evaluate

Lupin has informed that the company has enclosed a Press Release on 3rd April 2020 as regards receipt of the Establishment Inspection Report from the US FDA for the Company’s Aurangabad, India facility. The inspection for the facility was carried out by the US FDA between February 10, 2020 and February 14, 2020 and concluded with no observations. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE

Lupin Share Price

1615.85 20.95 (1.31%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.